The Horse

NOV 2018

The Horse:Your Guide To Equine Health Care provides monthly equine health care information to horse owners, breeders, veterinarians, barn/farm managers, trainer/riding instructors, and others involved in the hands-on care of the horse.

Issue link:

Contents of this Issue


Page 41 of 75

42 November 2018 The Horse | belly bandage available." The patented protected system and treatment method is designed to help prevent post-surgical hernias and reduce existing ones. The belt saves time, says Miesen, because it can be applied by one person, and it is cost-effective because it is durable and machine-washable and dryable. The ban- dage is available for patients from Mini to draft. It is also available in specialty sizes, such as for goats, cows, and pigs. For more information call 562/923-2868, email, or visit the website at Colorado Serum Company, Booth 1315 Since 1923 Colorado Serum Company and its subsidiary, Professional Biological Company, have manufactured a line of specialty veterinary vaccines and antise- rums. Colorado Serum Company is the largest producer of Tetanus Antitoxin, which is available in a concentrated, puri- fied form especially for the equine market. According to the company, a 2 mL dose provides 1500 IU of a clean and clear anti- toxin. Also available in a concentrated and purified form is the West Nile Antibody for treating infected horses or for short-term protection. Veterinarians can administer this product intravenously at a dosage of 10 mL per 100 pounds of body weight. For use as an aid in nonspecific treatment of equine infections and disease conditions, Normal Equine Serum provides supple- mental equine albumin, globulins, and as- sociated fluids. The company also provides Eastern and Western Encephalomyelitis Vaccine and Tetanus Toxoid for primary vaccinations and boostering. Visit the exhibit booth, and find more information at Dechra Veterinary Products, Booths 1028/1030/1029 Dechra Veterinary Products, located in Overland Park, Kansas, is the U.S. sales and marketing division of Dechra Phar- maceuticals PLC, a U.K.-listed company dedicated to the animal health care mar- ket. Dechra's equine product line includes Osphos (clodronate injection), the only intramuscular bisphosphonate indicated for the control of clinical signs associ- ated with navicular syndrome in horses, and the regenerative products Orthokine vet irap 10 and 60 and Osteokine PRP. Other products Dechra manufactures are Equidone (domperidone) Gel, Phycox EQ and MAX EQ joint supplements, and a full line of intravenous fluids under the Vetivex trade name. Dechra also carries a full line of topical dermatology products for horses, such as MiconaHex+Triz, as well as several ophthalmic ointments, including Vetropolycin (bacitracin- neomycin-polymyxin) veterinary oph- thalmic ointment and Vetropolycin HC (bacitracin-neomycin-polymyxin- hydrocortisone acetate 1%) veterinary ophthalmic ointment. EmberEquine by Juniper Systems, Booth 1407 EmberEquine is a complete ultrasound and record-keeping solution for managing the chaos of repro season. With an affordable premium ultrasound, a waterproof tablet, and user-friendly record-keeping software, EmberEquine says it has everything you need to improve efficiency and keep your practice up-to- date with the latest technology. Features include: ■ Powerful touchscreen ultrasound— connected to tablet for ultrasound image transfer ■ Mesa 2 Rugged Tablet—tough-as-nails tablet ■ Digital exam forms—simple and customizable ■ Client exam reports—including ultra- sound images ■ Billing codes—immediately accessible to office staff ■ Appointment scheduling—easily keep track of upcoming appointments ■ Free training Juniper Systems says that as data col- lection experts, they're excited to intro- duce this premium solution. Visit them in Booth 1407 to demo EmberEquine, or for more information please call 435/753- 1881. Equinosis LLC, Booths 2236/2238 Equinosis LLC was founded in 2007 in Columbia, Missouri, with its first objective to make the Equinosis Q with Lameness Locator biomechanical care platform available to equine veterinarians and elevate the quality of care, health, and well-being of horses. The Equinosis Q is a real-time handheld field-based 2018 AAEP CONVENTION PREVIEW Tildren ® (tiludronate disodium) BISPHOSPHONATE DRUG FOR INTRAVENOUS INFUSION. For use in horses only WARNINGS Do not use in horses intended for human consumption. NSAIDs should not be used concurrently with Tildren ® . Concurrent use of NSAIDs with Tildren ® may increase the risk of renal toxicity and acute renal failure. HUMAN WARNINGS Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure. CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION Tildren ® is indicated for the control of clinical signs associated with navicular syndrome in horses. CONTRAINDICATIONS Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol. Do not use in horses with impaired renal function or with a history of renal disease. Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions. PRECAUTIONS Approximately 30-45% of horses administered Tildren ® will demonstrate transient signs consistent with abdominal pain (colic). Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions. Colic signs can last approximately 90 minutes and may be intermittent in nature. Hand walking the horse may improve or resolve the colic signs in many cases. If a horse requires medical therapy, non-NSAID treatments should be administered due to the risk for renal toxicity. Avoid NSAID use. Horses should be well hydrated prior to administration of Tildren ® due to the potential nephrotoxic effects of Tildren ® . Tildren ® should be used with caution in horses receiving concurrent administration of other drugs that may reduce serum calcium (such as tetracyclines) or whose toxicity may exacerbate a reduction in serum calcium (such as aminoglycosides). Horses with HYPP (heterozygous or homozygous) may be at an increased risk for adverse reactions, including colic signs, hyperkalemic episodes, and death. The safe use of Tildren ® has not been evaluated in horses less than 4 years of age. Bisphosphonates should not be used in pregnant or lactating mares, or mares intended for breeding. Bisphosphonates have been shown to cause fetal developmental abnormalities in laboratory animals. DOSAGE AND ADMINISTRATION A single dose of Tildren ® should be administered as an intravenous infusion at a dose of 1 mg/kg (0.45 mg/ lb). The infusion should be administered slowly and evenly over 90 minutes to minimize the risk of adverse reactions. Maximum effect may not occur until 2 months post-treatment. For ADMINISTRATION INSTRUCTIONS (preparation of the reconstituted solution (20mg/mL) and preparation of the solution for infusion) and for complete product information, please read the insert contained within the product packaging. STORAGE Sterile powder (not reconstituted): Store at controlled room temperature 68°F-77°F (20°C-25°C). After preparation, the infusion should be administered either within 2 hours of preparation, or it can be stored for up to 24 hours under refrigeration at 36°F-46° F (2°C-8°C) and protected from light. HOW SUPPLIED Tildren ® is supplied in a 30mL glass vial as a white, sterile lyophilized powder containing 500mg tiludronic acid (as tiludronate disodium) packaged in a folding carton. For technical assistance or to report suspected adverse reactions, call 1-888-524-6332. INFORMATION FOR OWNERS Prior to Tildren ® administration, owners should be advised of the potential for adverse reactions in the hours or days following treatment. Adverse reactions within 4 hours post dosing may include signs of colic (manifested as pawing, stretching, getting up and down, sweating, ROLLING LOOKING AT mANKS KICKING AT BELLY FREQUENT GAS and pacing). Owners should be instructed to contact their veterinarian immediately if any adverse reactions are observed. Owners should be advised to consult with their veterinarian prior to the administration of an NSAID following Tildren ® administration. Made in Canada Patent information: U.S. patent 6,057,306 (Continued on page 46)

Articles in this issue

Links on this page

Archives of this issue

view archives of The Horse - NOV 2018